ROXITHROMYCIN - A NEW MOLECULE, A NEW PHARMACOKINETIC PROFILE

被引：5

作者：

NILSEN, OG

机构：

[1] Department of Pharmacology and Toxicology, Faculty of Medicine, University of Trondheim, Trondheim

[2] University of Trondheim, Trondheim

来源：

DRUG INVESTIGATION | 1991年 / 3卷

关键词：

D O I：

10.1007/BF03258332

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Roxithromycin is one of the newer macrolide antibiotics, and displays a superior gastrointestinal absorption, higher plasma concentrations and a longer plasma half-life than its analogue, erythromycin, thereby permitting once- or twice-daily administration. Its tissue distribution is extensive because of its high lipid solubility, and penetration into the respiratory tract tissues is adequate and comparable to that seen with erythromycin. Roxithromycin's intracellular penetration is superior to that of erythromycin, conferring bactericidal efficacy against intracellular pathogens such as Chlamydia and Legionella pneumophila. Roxithromycin displays nonlinear pharmacokinetics, with no appreciable accumulation and a low propensity for drug interactions.

引用

页码：28 / 32

页数：5

共 25 条

[1] Acar J.F., Saint-Salvi B., Blanc F., Concentration of roxithromycin in tear fluid and saliva after repeat dosing, British Journal of Clinical Practice, 42, (1988)
[2] Begue P., Kafetzis D.A., Albin H., Safran, Pharmacokinetics of roxithromycin in paediatrics, Journal of Antimicrobial Chemotherapy, 20, pp. 101-106, (1987)
[3] Bergogne-Berezin E., Tissue distribution of roxithromycin, Journal of Antimicrobial Chemotherapy, 20, pp. 113-120, (1987)
[4] Botto H., Carney M., Chretien P., Safran C., Study of the diffusion of roxithromycin into prostatic tissue after repeat oral dosing, British Journal of Clinical Practice, 42, (1988)
[5] Chastre J., Brun P., Fourtillan J.B., Soler P., Basset G., Et al., Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic, Antimicrobial Agents and Chemotherapy, 31, pp. 1312-1316, (1987)
[6] Croteau D., Bergeron M.G., LeBel M., Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography, Antimicrobial Agents and Chemotherapy, 32, pp. 561-565, (1988)
[7] Delaforge M., Sartori E., Mansuy D., Effects of roxithromycin on rat hepatic P-450 cytochromes: comparison with troleandomycin and erythromycin, British Journal of Clinical Practice, 42, pp. 67-69, (1988)
[8] De Rose V., Ferrara A., Mangiarotti P., Nonis A., Bertoletti R., Et al., Penetration of roxithromycin in bronchial secretions, International Journal of Clinical Pharmacology Research, 8, pp. 107-110, (1988)
[9] Fraschini F., Braga P.C., Biella G., Scaglione F., Montoli C., Et al., Pharmacokinetics and sputum levels of josamycin after single and multiple administrations in bronchopneumopathic patients, International Journal of Clinical Pharmacology Research, 3, pp. 203-208, (1983)
[10] Kazmierczak A., Pechinot A., Tillement J.P., Barre J., Chretien P., Et al., Roxithromycin pharmacokinetics compared with those of spiramycin and troleandomycin after a single oral dose, (1988)

← 1 2 3 →